Association of SARS-CoV-2 Seropositivity and Symptomatic Reinfection in Children in Nicaragua.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 06 2022
Historique:
entrez: 27 6 2022
pubmed: 28 6 2022
medline: 30 6 2022
Statut: epublish

Résumé

The impact of the SARS-CoV-2 pandemic on children remains unclear. Better understanding of the burden of COVID-19 among children and their risk of reinfection is crucial, as they will be among the last groups vaccinated. To characterize the burden of COVID-19 and assess how risk of symptomatic reinfection may vary by age among children. In this prospective, community-based pediatric cohort study conducted from March 1, 2020, to October 15, 2021, 1964 nonimmunocompromised children aged 0 to 14 years were enrolled by random selection from the Nicaraguan Pediatric Influenza Cohort, a community-based cohort in District 2 of Managua, Nicaragua. Additional newborn infants aged 4 weeks or younger were randomly selected and enrolled monthly via home visits. Prior COVID-19 infection as confirmed by positive anti-SARS-CoV-2 antibodies (receptor binding domain and spike protein) or real-time reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed COVID-19 infection at least 60 days before current COVID-19 infection. Symptomatic COVID-19 cases confirmed by real-time RT-PCR and hospitalization within 28 days of symptom onset of a confirmed COVID-19 case. This cohort study assessed 1964 children (mean [SD] age, 6.9 [4.4] years; 985 [50.2%] male). Of 1824 children who were tested, 908 (49.8%; 95% CI, 47.5%-52.1%) were seropositive during the study. There were also 207 PCR-confirmed COVID-19 cases, 12 (5.8%) of which were severe enough to require hospitalization. Incidence of COVID-19 was highest among children younger than 2 years (16.1 cases per 100 person-years; 95% CI, 12.5-20.5 cases per 100 person-years), which was approximately 3 times the incidence rate in any other child age group assessed. In addition, 41 symptomatic SARS-CoV-2 episodes (19.8%; 95% CI, 14.4%-25.2%) were reinfections. In this prospective, community-based pediatric cohort study, rates of symptomatic and severe COVID-19 were highest among the youngest participants, with rates stabilizing at approximately 5 years of age. In addition, symptomatic reinfections represented a large proportion of symptomatic COVID-19 cases.

Identifiants

pubmed: 35759261
pii: 2793625
doi: 10.1001/jamanetworkopen.2022.18794
pmc: PMC9237791
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2218794

Commentaires et corrections

Type : UpdateOf
Type : CommentIn

Références

Epidemiol Infect. 2021 Oct 20;149:e247
pubmed: 35172912
Nat Commun. 2021 Jan 11;12(1):267
pubmed: 33431879
Pediatr Pulmonol. 2021 Aug;56(8):2495-2502
pubmed: 34102037
Pediatr Infect Dis J. 2021 Jan;40(1):e7-e11
pubmed: 33093428
Sci Rep. 2021 May 13;11(1):10231
pubmed: 33986390
Am J Epidemiol. 1990 Feb;131(2):373-5
pubmed: 2296988
BMC Infect Dis. 2015 Nov 09;15:504
pubmed: 26553094
Swiss Med Wkly. 2021 Sep 17;151:w30058
pubmed: 34546012
Influenza Other Respir Viruses. 2022 Jan;16(1):34-47
pubmed: 34796674
Clin Chem. 2020 Apr 1;66(4):549-555
pubmed: 32031583
Clin Infect Dis. 2022 Aug 24;75(1):e257-e266
pubmed: 34411230
J Athl Train. 2021 Jun 1;56(6):542-547
pubmed: 34375980
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Arch Dis Child. 2021 Jul;106(7):680-686
pubmed: 33172887
PLoS Med. 2007 Oct 16;4(10):e296
pubmed: 17941714
Aging Male. 2020 Dec;23(5):1416-1424
pubmed: 32508193
JAMA Pediatr. 2021 Feb 1;175(2):176-184
pubmed: 33226415
Nature. 2021 Feb;590(7844):140-145
pubmed: 33137809
Int J Pediatr. 2020 Nov 18;2020:9680905
pubmed: 33299428
Ital J Pediatr. 2021 Aug 26;47(1):177
pubmed: 34446085
BMC Pediatr. 2021 Mar 25;21(1):144
pubmed: 33765980
Vaccine. 2021 Jan 22;39(4):667-677
pubmed: 33342635
Lancet Child Adolesc Health. 2021 Oct;5(10):708-718
pubmed: 34358472
JAMA Netw Open. 2021 Sep 1;4(9):e2124343
pubmed: 34491353
Int J Pediatr. 2021 Oct 06;2021:2185161
pubmed: 34659422
Science. 2021 Feb 12;371(6530):741-745
pubmed: 33436525
Lancet Child Adolesc Health. 2020 Sep;4(9):653-661
pubmed: 32593339

Auteurs

John Kubale (J)

Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor.

Angel Balmaseda (A)

Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua.

Aaron M Frutos (AM)

Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor.

Nery Sanchez (N)

Sustainable Sciences Institute, Managua, Nicaragua.
Centro de Salud Sócrates Flores Vivas, Ministry of Health, Managua, Nicaragua.

Miguel Plazaola (M)

Sustainable Sciences Institute, Managua, Nicaragua.

Sergio Ojeda (S)

Sustainable Sciences Institute, Managua, Nicaragua.
Centro de Salud Sócrates Flores Vivas, Ministry of Health, Managua, Nicaragua.

Saira Saborio (S)

Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua.
Sustainable Sciences Institute, Managua, Nicaragua.

Roger Lopez (R)

Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua.
Sustainable Sciences Institute, Managua, Nicaragua.

Carlos Barilla (C)

Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua.

Gerald Vasquez (G)

Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua.

Hanny Moreira (H)

Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua.

Anna Gajewski (A)

Sustainable Sciences Institute, Managua, Nicaragua.

Lora Campredon (L)

Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor.

Hannah E Maier (HE)

Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor.

Mahboob Chowdhury (M)

Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor.

Cristhiam Cerpas (C)

Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua.
Sustainable Sciences Institute, Managua, Nicaragua.

Eva Harris (E)

Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley.

Guillermina Kuan (G)

Sustainable Sciences Institute, Managua, Nicaragua.
Centro de Salud Sócrates Flores Vivas, Ministry of Health, Managua, Nicaragua.

Aubree Gordon (A)

Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH